Skip to main content
VECTUS BIOSYSTEMS LIMITED logo

VECTUS BIOSYSTEMS LIMITED — Investor Relations & Filings

Ticker · VBS ISIN · AU000000VBS9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 312 across all filing types
Latest filing 2024-05-29 Share Issue/Capital Cha…
Country AU Australia
Listing ASX VBS

About VECTUS BIOSYSTEMS LIMITED

https://vectusbiosystems.com.au/

Vectus Biosystems Limited is a drug discovery and development company focused on creating therapeutic candidates for the treatment of fibrosis and hypertension. The company utilizes a proprietary library of mimetic compounds to address tissue scarring and organ damage in the heart, kidneys, and liver. Its lead drug candidate, VB0004, is designed to treat high blood pressure and reverse established fibrosis. Complementing its pharmaceutical research, the company developed the Accugen platform, which provides a system for the precise quantification of DNA and RNA through quantitative polymerase chain reaction (qPCR) technology. By focusing on the reversal of fibrotic damage rather than symptom management, the company seeks to address significant unmet needs in chronic disease management and regenerative medicine.

Recent filings

Filing Released Lang Actions
Cleansing Notice 1 page 168.8KB
Share Issue/Capital Change Classification · 100% confidence The document is a short announcement (1918 characters) about the issue of new shares by Vectus Biosystems Limited. It includes a Cleansing Notice under section 708A(5)(e) of the Corporations Act 2001, which is a regulatory compliance statement related to the share issuance. The document does not contain financial statements or detailed financial analysis, nor does it present a full report. It is an announcement of a share issue event, specifically the issuance of shares upon exercise of options by an employee. According to the filing definitions, announcements regarding new share issues or capital changes fall under the category 'Share Issue/Capital Change' (Code: SHA). The document is not a full report, nor a regulatory filing or report publication announcement, but a direct announcement of a capital change event.
2024-05-29 English
Application for quotation of securities - VBS 6 pages 18.6KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement for the application for quotation of securities. It details the issuance and quotation of new securities resulting from options exercised or convertible securities converted. The document includes specifics such as the number of securities, issue date, and class of securities. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement related to capital changes and securities quotation. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is the announcement itself, not a report publication or certification.
2024-05-28 English
Appointment of Interim Chief Technology Officer 1 p
Board/Management Information Classification · 100% confidence The document is an announcement dated 23 May 2024 from Vectus Biosystems Limited regarding the appointment of an interim Chief Technology Officer. It provides details about the appointee's background and the company's plans related to clinical trials. There is no financial data, no mention of a report or filing, and no regulatory or legal content. The document is clearly an announcement about a management change, specifically the appointment of a senior executive. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on this appointment, confirming it is not a full report or other filing type.
2024-05-22 English
Passing of Vectus CEO 1 page 141.7KB
Board/Management Information Classification · 95% confidence The document is an announcement from Vectus Biosystems Limited regarding the passing of their CEO, Dr Karen Duggan. It includes condolences, a brief biography, and mentions upcoming steps for appointing an interim CTO and continuing company activities. There is no financial data, no report attached or referenced as being published, no voting results, no regulatory certifications, no earnings or interim report data, and no mention of any specific filings or financial statements. The document is a company announcement about a management event (the death of the CEO) and plans for interim management. This fits best under Board/Management Information (MANG), which covers announcements of changes in senior management or board members. The document length is 3620 characters, which is short but contains substantive content about management changes rather than just a notice or report publication. Therefore, the classification is MANG with high confidence.
2024-05-19 English
Final Director's Interest Notice 3Z - KD 1 page 139
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including shares held and interests in securities not registered in the director's name. The document also notes the date the director ceased to be a director. This is a report of personal share transactions and holdings by a company director, which fits the definition of Director's Dealing filings. The document length is short and focused solely on director share interests, with no financial statements or other report content. Therefore, the correct classification is Director's Dealing (DIRS).
2024-05-19 English
Quarterly Activities & Appendix 4C Cash Flow Reports 7 pages 444.9KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report and Appendix 4C' and references ASX Listing Rule 4.7B, which mandates quarterly reporting for entities listed on the Australian Securities Exchange. It contains detailed financial data including cash flow statements, operating activities, investing activities, financing activities, and cash available for future operations. The document covers the quarter ended 31 March 2024 and includes substantive financial data and analysis, not just an announcement or summary. This matches the definition of an Interim / Quarterly Report (IR). It is not an Annual Report (10-K), Earnings Release (ER), or Regulatory Filing (RNS) because it contains detailed financial statements and operational commentary for a quarter. Therefore, the correct classification is IR with high confidence.
2024-04-29 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.